Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of dolutegravir versus raltegravir in treatment-experienced, integrase inhibitor-naive adults with HIV-1
NL-OMON38097Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Human immunodeficiency virus infection type 1 comparing Dolutegravir + optimized background regimen with Raltegravir + optimized background regimen (2 arms). Primary endpoint: Proportion with HIV-1 RNA <50 copies/mL at week 48. Started Dec 2010; status: active, not recruiting.
02
Drugs
dolutegravirraltegravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON38097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38097.